# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN-TD
- Date: 1980-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Evangeline Moss, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood. **S**

## History of present illness

Ms. Jordan returns six weeks after her second ocrelizumab half-dose. During the first infusion she had a scratchy throat that settled when the infusion was slowed; the second infusion went without a reaction. She has had no infections, cold sores, or diarrhea. Physical therapy started four weeks ago through a second provider, after the first service could not offer a date; she has had six sessions and does her home program most days, and she now uses a rollator at home for longer distances. Summer has brought heat sensitivity: her legs feel heavier on hot afternoons and recover when she cools down, and she has started using a cooling vest. She gets up once a night or less. Her mood is steady. **S**

| Element | Detail |
|---|---|
| Infusions | Mild throat irritation with the first, settled by slowing; none with the second |
| Infections | None |
| Physical therapy | Started four weeks ago through a second provider; six sessions |
| Heat | Legs heavier on hot afternoons, recover with cooling |
| Mood | PHQ-9 3 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Afternoon fatigue, worse in the heat; no fever |
| Gastrointestinal | Negative | No diarrhea or abdominal pain |
| Genitourinary | Negative | Up once a night or less; no burning |
| Integumentary | Negative | No rash or cold sores |
| Neurological | Positive | Temporary heaviness of the legs in the heat; no new symptom lasting more than a day |
| Psychiatric | Negative | Mood steady |

6 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 1954 units (50 mcg) oral capsule, one capsule daily **S**
- Baclofen 10 mg oral tablet, one tablet three times a day **S**
- Mirabegron 25 mg extended-release oral tablet, one tablet daily **S**
- Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 83.5 kg; BMI 27.9 kg/m². All vital signs are synthetic.

White cells: 5.9 10*3/uL; Lymphocytes (absolute): 1.4 10*3/uL; Hemoglobin: 13.4 g/dL; Platelets: 248 10*3/uL; CD19 B cells (absolute): 3 /uL (low); ALT: 20 U/L; 25-hydroxyvitamin D: 34 ng/mL; PHQ-9: 3. All results are synthetic.

## Change since baseline

- White cells: 6.4 10*3/uL at baseline, 5.9 10*3/uL at this visit **S**
- Lymphocytes (absolute): 1.9 10*3/uL at baseline, 1.4 10*3/uL at this visit **S**
- Hemoglobin: 13.2 g/dL at baseline, 13.4 g/dL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 248 10*3/uL at this visit **S**
- ALT: 18 U/L at baseline, 20 U/L at this visit **S**
- 25-hydroxyvitamin D: 17 ng/mL (low) at baseline, 34 ng/mL at this visit **S**
- PHQ-9: 6 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 118/74, pulse 74; temperature 36.8 °C |
| Neurological | Spastic gait with a cane, as before; modified Ashworth 1+ in both legs; EDSS 6.0; timed 25-foot walk 11.1 seconds |
| Skin | No rash |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Active primary progressive multiple sclerosis** (G35.B1). Ocrelizumab started, with a mild first-infusion reaction only. White cells 5.9, lymphocytes 1.4, hemoglobin 13.4 g/dL, platelets 248; CD19 B cells 3 per microliter, depleted as expected; ALT 20 U/L. Disability stable. The heat-related heaviness is pseudo-relapse, not new disease activity. **S**
   - Next dose, 600 mg, six months after the first half-dose.
   - Re-baseline brain MRI before the October review.
   - Cooling vest, air conditioning and cool drinks; morning teaching where she can.
2. **Vitamin D deficiency** (E55.9). 25-hydroxyvitamin D 34 ng/mL after four months of vitamin D3: replete. **S**
   - Continue vitamin D3 1954 units daily; recheck yearly.
   - Bone density at the preventive visit.
3. **Spastic gait and fall risk** (R26.89). Physical therapy under way; rollator for longer distances at home; no falls. **S**
   - Continue physical therapy and the home program.
   - Scooter assessment for campus distances when she wants one.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | New or worsening symptoms (relapse, pseudo-relapse with heat or infection) | Every visit | Completed today | No relapse; heat-related pseudo-relapse explained |
| Examination | Disability: EDSS and timed 25-foot walk | Every visit, and at least every 6 months | Completed today | EDSS 6.0; timed 25-foot walk 11.1 seconds |
| Medication safety | Infusion reactions and infections | Each infusion, and every visit | Completed today | Mild throat irritation with the first infusion, settled by slowing; none with the second; no infections since |
| Laboratory | Blood count with absolute lymphocytes | Before the first dose, then before each dose | Completed today | White cells 5.9, lymphocytes 1.4, hemoglobin 13.4, platelets 248; CD19 3 per microliter (depleted, expected) |
| Laboratory | Liver tests | Before the first dose, then with symptoms and before each dose | Completed today | ALT 20 U/L |
| Laboratory | Hepatitis B surface antibody after vaccination | One to two months after the series in someone on immune therapy | Completed today | Protective level after two doses |
| Examination | Spasticity (modified Ashworth) and baclofen tolerance | Every visit | Completed today | Modified Ashworth 1+ on baclofen 10 mg three times a day |
| Examination | Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron | Every visit | Completed today | Nocturia once or less; blood pressure 118/74 on mirabegron |
| Referral | Falls, walking aids and physical therapy | Every visit | Completed today | Physical therapy started four weeks ago through a second provider; rollator at home; no falls |
| Self-management | Fatigue and heat sensitivity | Every visit | Completed today | Heat sensitivity; cooling vest started |
| Laboratory | 25-hydroxyvitamin D | At baseline, 8 to 12 weeks after repletion, then yearly | Completed today | 34 ng/mL after repletion |
| Imaging | Bone density | Once for reduced mobility and earlier steroid courses; repeat by risk | Due | At the preventive visit |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 months and with any change | Completed today | PHQ-9 3 |
| Examination | Concentration and word-finding | At intake, then yearly or with concern | Completed today | No concern raised by her; lectures and writing unaffected |
| Medication safety | Breast cancer screening (ocrelizumab label: standard screening) | Every two years from 40 | Due | Mammogram to be ordered at the preventive visit |

## Goal progress

- Diagnosis confirmed and classified, vaccines completed at least two weeks before therapy, and a disease-modifying therapy started within ten weeks. Outcome by 1980-06-29: Primary progressive disease confirmed at two weeks; vaccines finished at five weeks; ocrelizumab started at nine weeks. **S**
- No falls through eight months. In progress; target 1980-10-26. **S**
- 25-hydroxyvitamin D at least 30 ng/mL within four months. Outcome by 1980-06-29: 34 ng/mL at four months. **S**
- Up no more than once a night to pass urine within three months. Outcome by 1980-06-29: Once a night or less on mirabegron. **S**
- Keep her full teaching and speaking schedule with the accommodations she chooses. In progress; target 1980-10-26. **S**
- No new or enlarging T2 lesions on the re-baseline MRI. In progress; target 1980-10-26. **S**

## Guideline basis

- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018), American Academy of Neurology (Neurology)
- Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019), American Academy of Neurology (Neurology)
- OCREVUS (ocrelizumab) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Genentech label)
- Multiple sclerosis in adults: management (NG220) (2022), National Institute for Health and Care Excellence
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026), Aether Forge

## Follow-up

- Preventive visit in seven weeks with bone density and the mammogram order. Re-baseline brain MRI and review in four months, before the 600 mg dose. **S**
- Next scheduled visit 1980-08-17: periodic adult preventive visit. **S**
